GlaxoSmithKline Plc has issued improved guidance for adjusted earnings per share for 2018 following an increase in sales at constant exchange rates for the third quarter and first nine months, and a better operating margin. In a teleconference with journalists on 31 October, Emma Walmsley, the chief executive, highlighted sales of the company’s shingles’ vaccine Shingrix, the HIV medicines Triumeq and Tivicay, and new respiratory products.
